Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xylometazoline · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Xylometazoline | DRUG | - |
Inclusion Criteria: * Over 18 years * Have had moderate common cold symptoms for less than 36 hours. Exclusion Criteria: * Congested/runny nose for more than two continuous weeks in the previous 12 months * Deviated septum or nasal polyps * Recent use of antibiotics * Recent sinusitis Other prot...
Xylometazoline is used for the relief of nasal congestion associated with the common cold. It is a small molecule being developed by Novartis AG for this indication, and it is currently in Phase 3 clinical development.
Xylometazoline is a decongestant that works by constricting blood vessels in the nasal passages, which reduces swelling and congestion. It is being studied for its decongestant effect in patients with the common cold.
Xylometazoline is being developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker NVS. The drug is currently in Phase 3 clinical trials for the treatment of common cold symptoms.
Xylometazoline is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is studying its decongestant effects in patients with the common cold.
Xylometazoline has one completed Phase 3 clinical trial, identified as NCT00452270. This trial, titled 'Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold,' enrolled 60 participants in the United Kingdom.
Xylometazoline is a specific decongestant compound. It is being studied for its effects on nasal congestion in the common cold, and its clinical trial focuses on the timing of its decongestant effect and its impact on sleep and general well-being.